Logo image of HRTX

HERON THERAPEUTICS INC (HRTX) Stock Fundamental Analysis

NASDAQ:HRTX - Nasdaq - US4277461020 - Common Stock - Currency: USD

2  0 (0%)

After market: 2 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HRTX. HRTX was compared to 558 industry peers in the Biotechnology industry. HRTX has a bad profitability rating. Also its financial health evaluation is rather negative. HRTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HRTX had negative earnings in the past year.
HRTX had a negative operating cash flow in the past year.
In the past 5 years HRTX always reported negative net income.
In the past 5 years HRTX always reported negative operating cash flow.
HRTX Yearly Net Income VS EBIT VS OCF VS FCFHRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

HRTX's Return On Assets of -3.30% is amongst the best of the industry. HRTX outperforms 88.53% of its industry peers.
Industry RankSector Rank
ROA -3.3%
ROE N/A
ROIC N/A
ROA(3y)-42.67%
ROA(5y)-52.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HRTX Yearly ROA, ROE, ROICHRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 73.97%, HRTX belongs to the top of the industry, outperforming 83.15% of the companies in the same industry.
In the last couple of years the Gross Margin of HRTX has grown nicely.
HRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y4.86%
HRTX Yearly Profit, Operating, Gross MarginsHRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
HRTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HRTX has been increased compared to 5 years ago.
The debt/assets ratio for HRTX has been reduced compared to a year ago.
HRTX Yearly Shares OutstandingHRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
HRTX Yearly Total Debt VS Total AssetsHRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

HRTX has an Altman-Z score of -9.48. This is a bad value and indicates that HRTX is not financially healthy and even has some risk of bankruptcy.
HRTX's Altman-Z score of -9.48 is on the low side compared to the rest of the industry. HRTX is outperformed by 72.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.48
ROIC/WACCN/A
WACC6.9%
HRTX Yearly LT Debt VS Equity VS FCFHRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

HRTX has a Current Ratio of 2.40. This indicates that HRTX is financially healthy and has no problem in meeting its short term obligations.
HRTX has a worse Current ratio (2.40) than 70.79% of its industry peers.
HRTX has a Quick Ratio of 1.76. This is a normal value and indicates that HRTX is financially healthy and should not expect problems in meeting its short term obligations.
HRTX's Quick ratio of 1.76 is on the low side compared to the rest of the industry. HRTX is outperformed by 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 1.76
HRTX Yearly Current Assets VS Current LiabilitesHRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.16% over the past year.
The Revenue has grown by 12.43% in the past year. This is quite good.
The Revenue has been decreasing by -0.24% on average over the past years.
EPS 1Y (TTM)90.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)12.43%
Revenue growth 3Y18.69%
Revenue growth 5Y-0.24%
Sales Q2Q%12.21%

3.2 Future

The Earnings Per Share is expected to grow by 41.83% on average over the next years. This is a very strong growth
HRTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.97% yearly.
EPS Next Y73.56%
EPS Next 2Y66%
EPS Next 3Y63.14%
EPS Next 5Y41.83%
Revenue Next Year12.54%
Revenue Next 2Y12.56%
Revenue Next 3Y13.85%
Revenue Next 5Y12.97%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HRTX Yearly Revenue VS EstimatesHRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
HRTX Yearly EPS VS EstimatesHRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

HRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 29.41, which means the current valuation is very expensive for HRTX.
HRTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. HRTX is cheaper than 90.68% of the companies in the same industry.
HRTX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 21.03, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 29.41
HRTX Price Earnings VS Forward Price EarningsHRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HRTX Per share dataHRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HRTX's earnings are expected to grow with 63.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66%
EPS Next 3Y63.14%

More info and screens

0

5. Dividend

5.1 Amount

HRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HERON THERAPEUTICS INC

NASDAQ:HRTX (6/20/2025, 8:00:02 PM)

After market: 2 0 (0%)

2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners81%
Inst Owner Change7.14%
Ins Owners0.63%
Ins Owner Change11.73%
Market Cap305.12M
Analysts84.44
Price Target6.38 (219%)
Short Float %22.72%
Short Ratio22.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)210.25%
Min EPS beat(2)173.52%
Max EPS beat(2)246.99%
EPS beat(4)3
Avg EPS beat(4)96.3%
Min EPS beat(4)-47.06%
Max EPS beat(4)246.99%
EPS beat(8)6
Avg EPS beat(8)64.69%
EPS beat(12)8
Avg EPS beat(12)43.56%
EPS beat(16)10
Avg EPS beat(16)31.82%
Revenue beat(2)2
Avg Revenue beat(2)4.47%
Min Revenue beat(2)1.93%
Max Revenue beat(2)7%
Revenue beat(4)2
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-12.91%
Max Revenue beat(4)7%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)6
Avg Revenue beat(12)0.93%
Revenue beat(16)7
Avg Revenue beat(16)-2.78%
PT rev (1m)25%
PT rev (3m)4.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)12.52%
EPS NY rev (3m)22.23%
Revenue NQ rev (1m)0.37%
Revenue NQ rev (3m)-1.99%
Revenue NY rev (1m)-0.47%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 29.41
P/S 2.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)0.07
Fwd EY3.4%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.97
BVpS-0.19
TBVpS-0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.97%
FCFM N/A
ROA(3y)-42.67%
ROA(5y)-52.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y4.86%
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.1%
Cap/Sales 1.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 1.76
Altman-Z -9.48
F-Score4
WACC6.9%
ROIC/WACCN/A
Cap/Depr(3y)61.69%
Cap/Depr(5y)104.8%
Cap/Sales(3y)1.37%
Cap/Sales(5y)3.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y73.56%
EPS Next 2Y66%
EPS Next 3Y63.14%
EPS Next 5Y41.83%
Revenue 1Y (TTM)12.43%
Revenue growth 3Y18.69%
Revenue growth 5Y-0.24%
Sales Q2Q%12.21%
Revenue Next Year12.54%
Revenue Next 2Y12.56%
Revenue Next 3Y13.85%
Revenue Next 5Y12.97%
EBIT growth 1Y95.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.89%
OCF growth 3YN/A
OCF growth 5YN/A